PIK3CA and posterior cortical atrophy: Our data identified clinically relevant PI3K isoform inhibitors (alpelisib [PI3Kαi]; AZD8186 [PI3Kβi]) + MIA-602 or -690 as a novel strategy for the treatment of PCa/CRPC/NEPC.